{"name":"Oxurion","slug":"oxurion","ticker":"","exchange":"","domain":"","description":"Oxurion is a biopharmaceutical company focused on the development of innovative treatments for retinal disorders, with a strong emphasis on diabetic macular edema and other ocular diseases. The company has a robust pipeline of drug candidates, including several in clinical trials, and collaborates with leading pharmaceutical partners to advance its therapeutic programs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"THR-149 dose level 1","genericName":"THR-149 dose level 1","slug":"thr-149-dose-level-1","indication":"Other","status":"phase_2"},{"name":"THR-149 dose level 2","genericName":"THR-149 dose level 2","slug":"thr-149-dose-level-2","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"THR-149 dose level 1","genericName":"THR-149 dose level 1","slug":"thr-149-dose-level-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"THR-149 dose level 2","genericName":"THR-149 dose level 2","slug":"thr-149-dose-level-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPYWVKY3BlSzNIVDBtbS1YMjRZNHhMTXRiSmF4cTBkTVpiMXctTlpwbVBpZl85cGtNWWRCQlIwMEtNZDVTRlk0a0VSbFN5SHlKMDB0WmlVZi1NRmpZQlVtSzVtMW5CQXRPbktPRTRfRlFCMXZ5b2ZrNXFOX0JnajRqMVdRZ19ES2dfTENHVXM4eERFWlp3Xy1wQTM5UdIBmwFBVV95cUxPYWVKY3BlSzNIVDBtbS1YMjRZNHhMTXRiSmF4cTBkTVpiMXctTlpwbVBpZl85cGtNWWRCQlIwMEtNZDVTRlk0a0VSbFN5SHlKMDB0WmlVZi1NRmpZQlVtSzVtMW5CQXRPbktPRTRfRlFCMXZ5b2ZrNXFOX0JnajRqMVdRZ19ES2dfTENHVXM4eERFWlp3Xy1wQTM5UQ?oc=5","date":"2026-04-07","type":"pipeline","source":"actusnews.com","summary":"Postponement Annual Shareholders Meeting - actusnews.com","headline":"Postponement Annual Shareholders Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQVFpmeHBYX0Mxcy1GOE5iY0dCNVgtTXZIVTYzY25VSVhubEo3YjU2ekxZRVVkeG1HcXZKNWo0YUg4U2FxLUFqTDBaUzFoeFhVQkd2M3kxeUlGNG9HYVdTUDlWSEl4TnVHR0lySklxTEVRemNoWDdmVDZfbi1aSmRfN0RNNV94SFZhY0VaUFYxRGNWS1AwQ0J4VEh2Sm1GYTl1eEFsM2Y5ZlpJS3UyTl9qODNmTzlBLWdKRm1TYjRn?oc=5","date":"2026-03-19","type":"deal","source":"ideal-investisseur.fr","summary":"Oxurion Aims to Acquire a European CRO Valued at €3.7 Million - ideal-investisseur.fr","headline":"Oxurion Aims to Acquire a European CRO Valued at €3.7 Million - ideal","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-19","type":"pipeline","source":"actusnews.com","summary":"Oxurion signs a letter of intent for the acquisition of an international CRO - actusnews.com","headline":"Oxurion signs a letter of intent for the acquisition of an international CRO","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-16","type":"pipeline","source":"actusnews.com","summary":"Axiodis CRO accelerates its sales and marketing strategy to support ambitious growth driven by Oxurion - actusnews.com","headline":"Axiodis CRO accelerates its sales and marketing strategy to support ambitious growth driven by Oxurion","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-19","type":"pipeline","source":"actusnews.com","summary":"Oxurion announces the temporary suspension of the financing programme dedicated to investments in digital… - actusnews.com","headline":"Oxurion announces the temporary suspension of the financing programme dedicated to investments in digital…","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPQTRFblotODlULUo0eHkzR0FDaGlvcnFBYjY1OWlIWEhueERJYVA2LXR5b1hxZUVPWlk4V1plMV80Y3BfcF9RSEVkRGNOV0FINmg4bTY5Z2lTaEVncS1XT2RubFplZm81ZndnUmZVbDlJRHVZaWRUTDBhTFpBU3J5M1NEZFRQMHNaZnYzMkNQeXBleXI3Y29PbXY4dHZRbTV0SWxLYTd4T2EyTWF2aGQ5aU1rdkNiamlFTGdpeGVUZEoxOGhsLURzbTFpbmxzallZREJrdXhSN0M3SXo3UXVhT1dMWk5ZdmhER1E?oc=5","date":"2025-04-30","type":"regulatory","source":"PR Newswire","summary":"Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight - PR Newswire","headline":"Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQYWk1cm8zTHBMcHFYUXlWcTBEdlhrcVBwSE1nR1VxaW9fd2plV04zNlU1LXJXbDlDSDVuaHRGSzBueGVwbXhSLWlYamZXWkN3QUJmZFctWVQxSkFSRGRWOW0yYzRJb3pQLW5oaEtNTFJPVWh3VW8weUhBc0x5Q3ctenhwMm1obDJraEdpc29QQnhNRkwyd1Z1bjNzdVNmQk5oTHRDdm5JT0QtMFk?oc=5","date":"2024-11-12","type":"pipeline","source":"Medscape","summary":"Dry AMD Highlights From ASRS 2024 - Medscape","headline":"Dry AMD Highlights From ASRS 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5sU2ZlWmdXTTUxUjYwaWpOOTBKU2JmazcyeU40YVREOFlPanBXUWc0T3B4eXNjdDZjNTRfNTJuLUJpS0RlcUk2VEFpcXg1RWk2Z3JYY3lqVkFldlhTUGFDOVRRaklUdWlYYXIzR0l6OUlkSThfYUJLbDJiQWg?oc=5","date":"2023-12-29","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2023: Reneo reduces workforce by 70%; Oxurion cuts staff down to 10 - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2023: Reneo reduces workforce by 70%; Oxurion cuts staff down to 10","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQVlpmTUZpVUJYd3FIQ01MbjVaUnVOekRhckw5VzBHclR2bTNjS0NjMkVsVE5DYXpVRE4wenNsMWdScmdvZzBfeU8zZC10UGFSZFc4dFBtYUJIZUZYaFVQbVVKcjUzb1pRZHNfaWpOd21KcnM4bTJPNThUcGJJTWtkOGU3UUEwWjZmNzRfUVl4eDhlQjl3enFrQVdCVnh3bEhy?oc=5","date":"2022-05-24","type":"trial","source":"Pharmaceutical Technology","summary":"Oxurion discontinues the development of THR-687 despite promising preclinical data - Pharmaceutical Technology","headline":"Oxurion discontinues the development of THR-687 despite promising preclinical data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPYW9zWVBFNjdrU3NYeWJrT0dJdFg5Y3g5VDR4UERoNERmUF9qZTVGNHgwQnBzMmFvTFVXYkFaODJGWlRMeXB3QnpXRHVjZzhBc2RCQTEzeTRGU3FzYlRUTUlTMWdrNldpMlNsNXBhNGpLVU1qVXctVFJaQndFQmtwbUo1bmJZeFl2eGVLZnAyT1dqSVFEZkpVQklB?oc=5","date":"2021-06-25","type":"pipeline","source":"Fierce Biotech","summary":"Oxurion stops investing in cancer spinout, reduces head count - Fierce Biotech","headline":"Oxurion stops investing in cancer spinout, reduces head count","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1ocktVWlN5ZFctWUhvdVN4SDdoVmIwOGwxTkZNd0x2SXlwMEMzQjNFUTZXR3BLN2FWSm9jaF9palp6V0ZBN3FvQ3dBYjBxZnN1WW4tU0gtSmNlQ0dvVTM3VmU5RkFES3ZmZTVXcG5R?oc=5","date":"2018-11-15","type":"pipeline","source":"Pharma Voice","summary":"Trend: Creating Shared Value - Pharma Voice","headline":"Trend: Creating Shared Value","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}